A critical step forward in cancer care! The FDA has approved the use of niraparib and abiraterone acetate with prednisone in treating patients with BRCA-mutated castration-resistant prostate cancer. The green light comes backed by the robust efficacy data from the MAGNITUDE trial.
Read more about the FDA approval at
https://tinyurl.com/dzdvtm9m
Learn more about the MAGNITUDE trial at
https://pubmed.ncbi.nlm.nih.gov/36952634/